Omeros Corp

OMER is in a Stage 2 corrective reset within its broader long-term uptrend, and the Post-Capitulation pattern signals exhaustion of forced selling. Price is holding above the 9 and 21 EMAs and testing the 50 DMA after the recent flush low, supporting medium-term bullish posture. Short-term conditions are mixed, with price below resistance at the 21 EMA, so execution is deferred into a pullback or confirmation above intermediate EMAs—Stalk for entries on pullbacks into EMAs or upon acceptance above the 21 EMA.

• ↑Yartemlia Q1 gross revenue $11.1M, driving cash flow positivity.
• ↑Novo Nordisk partnership provides $240M upfront plus milestone upside.
• ↓EMA rejected efficacy data, delaying European market entry for Yartemlia.